A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

Annals of Oncology

Volumn 25, Issue 7, 2014, Pages 1333-1339

  Gralla, Richard J ^a   Bosnjak, S M ^b   Hontsa, A ^c   Balser, C ^d   Rizzi, G ^e   Rossi, G ^e   Borroni, M E ^e   Jordan, K ^f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^c Chernivtsi Regional Clinical Hospital   (Ukraine)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

^e HELSINN HEALTHCARE SA   (Switzerland)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

CINV; Multiple chemotherapy cycles; NEPA; Netupitant; Neurokinin 1 receptor antagonist; Palonosetron

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; IRINOTECAN; METOCLOPRAMIDE; NETUPITANT PLUS PALONOSETRON; NEUROKININ 1 RECEPTOR ANTAGONIST; OXALIPLATIN; PALONOSETRON; SEROTONIN 3 AGONIST; UNCLASSIFIED DRUG; DRUG COMBINATION; ISOQUINOLINE DERIVATIVE; NETUPITANT; PYRIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE;

ACUTE PSYCHOSIS; ADULT; ARTICLE; BLADDER CANCER; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ECG ABNORMALITY; ERUCTATION; FEMALE; HEAD AND NECK CANCER; HEADACHE; HEART DISEASE; HUMAN; LEUKOPENIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEOPLASM; NEUTROPENIA; OPEN STUDY; OVARY CANCER; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SINGLE DRUG DOSE; ST SEGMENT DEPRESSION; STOMACH CANCER; T WAVE; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; NAUSEA; NEOPLASMS; VOMITING;

ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HUMANS; ISOQUINOLINES; NAUSEA; NEOPLASMS; PYRIDINES; QUINUCLIDINES; VOMITING;

EID: 84903735622     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu096     Document Type: Article

References (7)

1. De Wit R, Herrstedt J, Rapoport B et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003; 22: 4105-4111.
2. De Wit R, Schmitz PIM, Verweij J et al. Analysis of cumulative probabilities shows that the efficacy of 5-HT3 antagonist prophylaxis is not maintained. J Clin Oncol 1996; 14: 644-651.
3. Rojas C, Slusher BS. Pharmacological mechanism of 5-HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 2012; 684(1-3): 1-7.
4. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 2011; 22(1): 30-38.
5. Hesketh P, Rossi G, Rizzi G et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014; 25: 1340-1346.
6. Aapro M, Rugo H, Rossi G et al. A randomized phase 3 study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25: 1328-1333.
7. Boccia R, Grunberg S, Franco-Gonzales E et al. Efficacy of oral palonosetron compared to intravenous palonosetron for prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Support Care Cancer 2013; 21(5): 1453-1460.